Fate Therapeutics, Inc.
FATE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $14 | $64 | $96 | $56 |
| % Growth | -78.5% | -34% | 72.4% | – |
| Cost of Goods Sold | $0 | $157 | $14 | $6 |
| Gross Profit | $14 | -$94 | $83 | $50 |
| % Margin | 100% | -147.4% | 85.7% | 89.5% |
| R&D Expenses | $135 | $173 | $320 | $216 |
| G&A Expenses | $74 | $81 | $84 | $57 |
| SG&A Expenses | $74 | $97 | $84 | $57 |
| Sales & Mktg Exp. | $0 | $15 | $0 | $0 |
| Other Operating Expenses | $15 | -$173 | -$14 | -$6 |
| Operating Expenses | $224 | $97 | $391 | $267 |
| Operating Income | -$210 | -$191 | -$308 | -$217 |
| % Margin | -1,542.6% | -299.9% | -320.2% | -388.6% |
| Other Income/Exp. Net | $24 | $30 | $27 | $5 |
| Pre-Tax Income | -$186 | -$161 | -$282 | -$212 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$186 | -$161 | -$282 | -$212 |
| % Margin | -1,366.5% | -253.3% | -292.5% | -379.9% |
| EPS | -1.64 | -1.64 | -2.91 | -2.24 |
| % Growth | 0% | 43.6% | -29.9% | – |
| EPS Diluted | -1.64 | -1.64 | -2.91 | -2.24 |
| Weighted Avg Shares Out | 114 | 98 | 97 | 95 |
| Weighted Avg Shares Out Dil | 114 | 98 | 97 | 95 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17 | $17 | $6 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $19 | $18 | $14 | $6 |
| EBITDA | -$177 | -$172 | -$295 | -$211 |
| % Margin | -1,295.4% | -271.1% | -305.9% | -378.1% |